CARE Consortium

CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. With a coalition of Europe’s best scientific minds from 37 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China it provides a multi-disciplinary team with proven expertise and capabilities in anti-viral drug development. Objectives & Strategy: The CARE consortium has three main goals: - The development of therapeutics to provide an emergency response towards the current COVID-19 pandemic - The development of therapeutics to address the current and/or future coronavirus outbreaks - The understanding of the physiopathology of COVID-19 and the discovery of immune markers contributing to the host immune responses to COVID-19 infection and their correlations with clinical and virological outcomes The project ambition is to accelerate development and use of effective therapies to COVID-19 patients in Europe and around the world, and generate a truly transformative treatment regimen. The project combines a focus on rapid emergency response with focus on long-term preparedness for future outbreaks. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, BILL & MELINDA GATES FOUNDATION, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE and UNIVERSITY OF DUNDEE.